Daniel Gerlach (@gerlach_d) 's Twitter Profile
Daniel Gerlach

@gerlach_d

Associate Scientific Director, Computational Biology Oncology at @boehringer 🧬 Data Scientist & KRAS, MDM2 , HER2 Research. Tweets are my own.

ID: 1325200380

linkhttps://www.linkedin.com/in/daniel-gerlach calendar_today03-04-2013 18:40:12

8,8K Tweet

1,1K Followers

505 Following

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C | Cancer Discovery | American Association for Cancer Research aacrjournals.org/cancerdiscover…

Anirban Maitra (@aiims1742) 's Twitter Profile Photo

Always great to hear the original RAScal Channing Der Der Lab at UNC talk about KRAS & KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) & 160 clinical trials. Absolutely amazing. David S. Hong MD

Always great to hear the original RAScal <a href="/cjder23/">Channing Der</a> <a href="/derlabunc/">Der Lab at UNC</a> talk about KRAS &amp; KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) &amp; 160 clinical trials. Absolutely amazing. 
<a href="/DavidHongMD/">David S. Hong MD</a>
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

#ELCC25 Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC: - ORR 38% - mPFS 9.8m, mDOR 15.1m - modest tox (diarrhea & rash) - 200mg dose selected for ph III Promising. Delighted Ph III RASolve trial of this agent, coming to 🇮🇪 ESMO - Eur. Oncology CancerTrialsIreland 🌈 @Oncoalert #LCSM

#ELCC25 
Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC:

- ORR 38%
- mPFS 9.8m, mDOR 15.1m
- modest tox (diarrhea &amp; rash)
- 200mg dose selected for ph III

Promising. Delighted Ph III RASolve trial of this agent, coming to 🇮🇪 
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/cancertrials_ie/">CancerTrialsIreland 🌈</a> @Oncoalert #LCSM
Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd) | Nature Communications idp.nature.com/authorize?resp…

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats G Curigliano MD PhD for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/p…

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats <a href="/curijoey/">G Curigliano MD PhD</a> for leading the DB06 trial that backed this approval!
astrazeneca.com/media-centre/p…
EMBL Events (@emblevents) 's Twitter Profile Photo

🧬💡 The EMBL Conference 'Cancer genomics' is now open for registration! Submit your abstract by 13 July and join the community of leading scientists and academic clinicians working on cancer genomics 👩🏾‍🔬👨🏻‍🔬 #EMBLCanGen 🗓️ 11 – 14 November 2025 📍 EMBL Heidelberg and Virtual

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…

Evolution of HER2 testing over 40 yrs.

IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging.

We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25.

Stay tuned.

nature.com/articles/s4157…
Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

⭐️With so many KRAS targeted drugs entering clinical trials pleased to share our editorial 👉🏼Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer 🚀🧬🎯 | JCO Oncology Practice JCO Oncology Practice ASCO OncoDaily ascopubs.org/doi/full/10.12…

Emil Lou, MD, PhD, FACP (@cancerassassin1) 's Twitter Profile Photo

The 2025 AACR Annual Meeting is coming up in a few short weeks. This post from the AACR details What to Know Before Heading to #AACR25 taking place in #Chicago April 25-30, 2025: aacr.org/blog/2025/04/0…

The 2025 <a href="/AACR/">AACR</a> Annual Meeting is coming up in a few short weeks. This post from the AACR details What to Know Before Heading to #AACR25 taking place in #Chicago April 25-30, 2025:

aacr.org/blog/2025/04/0…
Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors | Molecular Cancer Therapeutics | American Association for Cancer Research aacrjournals.org/mct/article/24…

Nature Reviews Drug Discovery (@natrevdrugdisc) 's Twitter Profile Photo

FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and the TROP2-targeted antibody-drug conjugate datopotamab deruxtecan for breast cancer

FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h
Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and the TROP2-targeted antibody-drug conjugate datopotamab deruxtecan for breast cancer
Emil Lou, MD, PhD, FACP (@cancerassassin1) 's Twitter Profile Photo

The AACR is on #Bluesky, where a lot of the online rigorous and respectful scientific discourse has taken place and grown since November. A lot more to come during the upcoming 2025 AACR Annual Meeting (#AACR25) April 25-30. @theaacr.bsky.social

The <a href="/AACR/">AACR</a> is on #Bluesky, where a lot of the online rigorous and respectful scientific discourse has taken place and grown since November. A lot more to come during the upcoming 2025 AACR Annual Meeting (#AACR25) April 25-30.  @theaacr.bsky.social
Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 (@bllphd) 's Twitter Profile Photo

Drug Development Is Slowing Down After Cuts at the #FDA Agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials ~3,500 workers were cut at the FDA, including Chief Medical Officer Dr. Hilary Marston and Dr. Peter Stein, who

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Emerging importance of HER3 in tumorigenesis and cancer therapy | Nature Reviews Clinical Oncology nature.com/articles/s4157…

Anirban Maitra (@aiims1742) 's Twitter Profile Photo

I know #AACR25 is coming up, but the program and roster for AACR Special Conference on #PancreaticCancer in Boston in the fall of 2025 is also up and available.... the attendance at this just keeps growing! Dr. Edna Cukierman, Ph.D. Laura DeLong Wood aacr.org/meeting/aacr-s…